glp-1 drugs with fewest side effects GI Adverse of Glucagon-Like Peptide-1 Receptor Agonists Part 1 of a 3-Part

Shima Hadidchi

Individuals interested in supporting gut microbiome balance and metabolic wellness may consider targeted probiotic supplements

Some sub-analyses of large clinical trials suggest that GLP-1RA and sodium-glucose cotransporter 2 inhibitor combination therapy may provide more significant reductions in heart failure hospitalization and renal composite events than each alone

Obesity and associated metabolic disorders such as type 2 diabetes mellitus and polycystic ovary syndrome are rising globally, contributing to infertility and adverse pregnancy outcomes

Adult-onset type 1 diabetes mellitus differs from the early onset form in terms of residual endogenous insulin secretion, comorbidities and baseline cardiorenal risk

Glucagon-like peptide 1 (GLP-1) is a cleavage product of the pre-proglucagon gene which is expressed in the -cells of the pancreas, the L-cells of the intestine, and neurons located in the caudal brainstem and hypothalamus